NO976122L - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents

AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes

Info

Publication number
NO976122L
NO976122L NO976122A NO976122A NO976122L NO 976122 L NO976122 L NO 976122L NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 L NO976122 L NO 976122L
Authority
NO
Norway
Prior art keywords
assay method
ligand antibodies
phase ligand
phase
antibodies
Prior art date
Application number
NO976122A
Other languages
English (en)
Other versions
NO976122D0 (no
NO324120B1 (no
Inventor
Kamon Shirakawa
Tomokazu Matsusue
Shigekazu Nagata
Man Sung Co
Maximiliano Vasquez
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/649,100 external-priority patent/US6114507A/en
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Publication of NO976122D0 publication Critical patent/NO976122D0/no
Publication of NO976122L publication Critical patent/NO976122L/no
Publication of NO324120B1 publication Critical patent/NO324120B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19976122A 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. NO324120B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18848095 1995-06-30
US08/649,100 US6114507A (en) 1995-06-30 1996-05-17 Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
PCT/JP1996/001820 WO1997002290A1 (en) 1995-06-30 1996-07-01 ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME

Publications (3)

Publication Number Publication Date
NO976122D0 NO976122D0 (no) 1997-12-29
NO976122L true NO976122L (no) 1998-02-27
NO324120B1 NO324120B1 (no) 2007-08-27

Family

ID=26504954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976122A NO324120B1 (no) 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene.

Country Status (8)

Country Link
EP (1) EP0842948B1 (no)
JP (1) JP3925663B2 (no)
CN (1) CN1196733A (no)
AU (1) AU724856B2 (no)
CA (1) CA2225852C (no)
NO (1) NO324120B1 (no)
NZ (1) NZ311174A (no)
WO (1) WO1997002290A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725329B2 (en) * 1996-09-02 2000-10-12 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
CA2309598A1 (en) 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
WO1999039737A1 (fr) * 1998-02-06 1999-08-12 Mochida Pharmaceutical Co., Ltd. Medicaments pour prevenir/traiter la maladie intestinale inflammatoire
WO1999058150A1 (en) * 1998-05-14 1999-11-18 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hepatic cirrhosis
DE69932434D1 (de) 1998-05-29 2006-08-31 Mochida Pharm Co Ltd Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4734739B2 (ja) * 2000-09-29 2011-07-27 東レ株式会社 哺乳動物のガン抑制方法
CN1283662C (zh) * 2002-03-21 2006-11-08 伊莱利利公司 拮抗性抗hFAS配基人类抗体及其片段
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
AU2004229501B2 (en) * 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
SI2428252T1 (sl) 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
JP2011506371A (ja) * 2007-12-12 2011-03-03 ピンチェル ソチエタ・レスポンサビリタ・リミタータ 抗Ｆａｓリガンド抗体を含有する天疱瘡の治療薬
US8540987B2 (en) 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
RU2556818C2 (ru) 2008-12-12 2015-07-20 Пинчел Срл СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ ЛИГАНДА Fas
CN102497886B (zh) * 2009-07-21 2016-01-20 玛丽皇后与斯特菲尔德学院 用于细胞内药物递送的Fas(Apo-1，CD95)靶向平台
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
DK3140653T3 (da) * 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
CN108290950B (zh) 2015-09-23 2022-01-28 阿珀吉科吉尼科斯股份公司 抗cd95l抗体
EP3592392B1 (en) * 2017-03-10 2023-09-13 University of Louisville Research Foundation, Inc. Fasl-engineered biomaterials with immunomodulatory function
US20250101120A1 (en) * 2022-01-21 2025-03-27 Beijing Solobio Genetechnology Co., Ltd. Antibodies specifically recognizing fasl and uses thereof
EP4514388A1 (en) 2022-04-26 2025-03-05 F. Hoffmann-La Roche AG Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1995010540A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
ATE387458T1 (de) * 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
CA2215905A1 (en) 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. Monoclonal antibody reacting specifically with fas ligand and process for producing the same

Also Published As

Publication number Publication date
NO976122D0 (no) 1997-12-29
CN1196733A (zh) 1998-10-21
AU6243596A (en) 1997-02-05
CA2225852A1 (en) 1997-01-23
AU724856B2 (en) 2000-10-05
CA2225852C (en) 2009-04-14
NO324120B1 (no) 2007-08-27
WO1997002290A1 (en) 1997-01-23
JP3925663B2 (ja) 2007-06-06
NZ311174A (en) 1999-04-29
EP0842948A4 (en) 2004-12-15
EP0842948B1 (en) 2009-04-22
EP0842948A1 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
NO976122L (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
NO996551L (no) Forbedrete anti-IgE-antistoffer og fremgangsmåte for forbedring av polypeptider
ID19197A (id) Pesawat pengolah informasi dan metode pengolah informasi
DE69632366D1 (de) Probenfördereinrichtung
DE69732511D1 (de) Verarbeitungsverfahren für Signale von Objekten mit sich bewegenden Teilen und Echographie-Vorrichtung dafür
DK0825946T3 (da) Fremgangsmåde til lastning og behandling af hydrocarboner
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
FI951040A0 (fi) Biospesifinen määritysmenetelmä
DE69638207D1 (de) Prozessor und Verarbeitungsverfahren für Dokumente
DE69427123D1 (de) Screeningverfahren für katalytische nicht-enzym-polypeptide und-proteine
FI950507A7 (fi) Määritysmenetelmä proteiinin määrittämiseksi biologisesta näytteestä
FI923025L (fi) Diagnostinen menetelmä synnytysajankohdan ennustamiseksi sekä siihen käytettävä reagenssipakkaus
DE69608277D1 (de) Probenanalysegerät
EP0699909A3 (en) Method for the determination of fibrinogen and reagent for its determination
FI931735A7 (fi) Menetelmä ei-spesifisten reaktioiden eliminoimiseksi immunoanalyysissä
DE69409379D1 (de) Ultraschallabtastgerät und -verfahren
KR970703146A (ko) 류마티스성 관절염의 치료방법 및 시약(method and reagents for the treatment of rheumatoid arthritis)
EP1079231A4 (en) Immunoassay reagents and immunoassay method
EP0831935A4 (en) GASEOUS ULTRASONIC CONTRAST AGENTS AND RELATED METHODS
FI964604L (fi) Menetelmä ja reagensseja nivelreuman hoitamiseksi
DK0780388T3 (da) 5HT1Dalfa og 5HT2A ligander
DE69426354D1 (de) Reagenz zur bestimmung von glucose
ZA944024B (en) Immunoassay reagents and methods for detecting brequinar and analoges
FI954948A7 (fi) Putkiliitos sekä menetelmä sen käyttämiseksi